Inflammation in psychopathology of depression: Clinical, biological, and therapeutic implications

BioMedicine (Netherlands)

Volumn 2, Issue 2, 2012, Pages 68-74

  Su, Kuan Pin ^a,b  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Anti inflammatory; Antidepressant; Cytokines; Depression; Docosahexaenoic acid (DHA); Eicosapentaenoic acid (EPA); Inflammation; Interferon (IFN ); Interleukin (IL); Omega 3 (n 3) polyunsaturated fatty acids (PUFAs)

Indexed keywords

ALPHA INTERFERON; CELECOXIB; CYTOKINE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEGA 3 FATTY ACID;

ANOREXIA; ANTIDEPRESSANT ACTIVITY; ANTIINFLAMMATORY ACTIVITY; APATHY; ARTHRALGIA; ATTENTION DEFICIT DISORDER; CARDIOVASCULAR DISEASE; COUGHING; CYTOKINE PRODUCTION; DEPRESSION; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; DYSPNEA; FATIGUE; FATTY ACID BLOOD LEVEL; FEVER; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HUMAN; HYPOMANIA; INFLAMMATION; MALAISE; MYALGIA; NEUROIMMUNOLOGY; NEUROPATHOLOGY; NEUROPSYCHIATRY; NONHUMAN; PAIN; PATHOPHYSIOLOGY; PHARYNGITIS; PUERPERAL DEPRESSION; RASH; REVIEW; RHINORRHEA; RISK BENEFIT ANALYSIS; SIDE EFFECT;

ANIMALIA; HEPATITIS C VIRUS;

EID: 84862764317     PISSN: 22118020     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomed.2012.03.002     Document Type: Review

References (91)

1. Murray C.J., Lopez A.D. Alternative projections of mortality and disability by cause 1990-2020: global burden of disease study. Lancet 1997, 349:1498-1504.
2. Belmaker R.H., Agam G. Major depressive disorder. N Engl J Med 2008, 358:55-68.
3. Hasler G., Drevets W.C., Manji H.K., Charney D.S. Discovering endophenotypes for major depression. Neuropsychopharmacology 2004, 29:1765-1781.
4. Maes M., Leonard B., Fernandez A., Kubera M., Nowak G., Veerhuis R., et al. (Neuro)inflammation and neuroprogression as new pathways and drug targets in depression: from antioxidants to kinase inhibitors. Prog Neuropsychopharmacol Biol Psychiatry 2011, 35:659-663.
5. Raison C.L., Capuron L., Miller A.H. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol 2006, 27:24-31.
6. Su K.P. Biological mechanism of antidepressant effect of omega-3 fatty acids: how does fish oil act as a 'mind-body interface'?. Neurosignals 2009, 17:144-152.
7. Qin L., Wu X., Block M.L., Liu Y., Breese G.R., Hong J.S., et al. Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia 2007, 55:453-462.
8. Konsman J.P., Parnet P., Dantzer R. Cytokine-induced sickness behaviour: mechanisms and implications. Trends Neurosci 2002, 25:154-159.
9. Smith R.S. The macrophage theory of depression. Med Hypotheses 1991, 35:298-306.
10. Hanisch U.K., Kettenmann H. Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat Neurosci 2007, 10:1387-1394.
11. Dantzer R., O'Connor J.C., Freund G.G., Johnson R.W., Kelley K.W. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 2008, 9:46-56.
12. Lu D.Y., Tsao Y.Y., Leung Y.M., Su K.P. Docosahexaenoic acid suppresses neuroinflammatory responses and induces heme oxygenase-1 expression in BV-2 microglia: implications of antidepressant effects for omega-3 fatty acids. Neuropsychopharmacology 2010, 35:2238-2248.
13. Maes M., Kubera M., Obuchowiczwa E., Goehler L., Brzeszcz J. Depression's multiple comorbidities explained by (neuro)inflammatory and oxidative and nitrosative stress pathways. Neuro Endocrinol Lett 2011, 32:7-24.
14. Gozzelino R., Jeney V., Soares M.P. Mechanisms of cell protection by heme oxygenase-1. Annu Rev Pharmacol Toxicol 2010, 50:323-354.
15. Hochstrasser T., Ullrich C., Sperner-Unterweger B., Humpel C. Inflammatory stimuli reduce survival of serotonergic neurons and induce neuronal expression of indoleamine 2,3-dioxygenase in rat dorsal raphe nucleus organotypic brain slices. Neuroscience 2011, 184:128-138.
16. Song C., Wang H. Cytokines mediated inflammation and decreased neurogenesis in animal models of depression. Prog Neuropsychopharmacol Biol Psychiatry 2011, 35:760-768.
17. Zhang F., Zhou H., Wilson B.C., Shi J.S., Hong J.S., Gao H.M. Fluoxetine protects neurons against microglial activation-mediated neurotoxicity. Parkinsonism Relat Disord 2012, 18:S213-S217.
18. Danese A., McEwen B.S. Adverse childhood experiences, allostasis, allostatic load, and age-related disease. Physiol Behav 2012, 106:29-39.
19. Katon W., Sullivan M.D. Depression and chronic medical illness. J Clin Psychiatry 1990, 51:3-11.
20. Su K.P. Mind-body interface: the role of n-3 fatty acids in psychoneuroimmunology, somatic presentation, and medical illness comorbidity of depression. Asia Pac J Clin Nutr 2008, 17:151-157.
21. Dieperink E., Willenbring M., Ho S.B. Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: a review. Am J Psychiatry 2000, 157:867-876.
22. Raison C.L., Demetrashvili M., Capuron L., Miller A.H. Neuropsychiatric adverse effects of interferon-alpha: recognition and management. CNS Drugs 2005, 19:105-123.
23. Dantzer R. Cytokine-induced sickness behaviour: a neuroimmune response to activation of innate immunity. Eur J Pharmacol 2004, 500:399-411.
24. Su K.P., Huang S.Y., Peng C.Y., Lai H.C., Huang C.L., Chen Y.C., et al. Phospholipase A2 and cyclooxygenase 2 genes influence the risk of interferon-alpha-induced depression by regulating polyunsaturated fatty acids levels. Biol Psychiatry 2010, 67:550-557.
25. Asnis G.M., De La G.R. Interferon-induced depression in chronic hepatitis C: a review of its prevalence, risk factors, biology, and treatment approaches. J Clin Gastroenterol 2006, 40:322-335.
26. Pariante C.M., Orru M.G., Baita A., Farci M.G., Carpiniello B. Treatment with interferon-alpha in patients with chronic hepatitis and mood or anxiety disorders. Lancet 1999, 354:131-132.
27. Bonaccorso S., Puzella A., Marino V., Pasquini M., Biondi M., Artini M., et al. Immunotherapy with interferon-alpha in patients affected by chronic hepatitis C induces an intercorrelated stimulation of the cytokine network and an increase in depressive and anxiety symptoms. Psychiatry Res 2001, 105:45-55.
28. Raison C.L., Borisov A.S., Majer M., Drake D.F., Pagnoni G., Woolwine B.J., et al. Activation of central nervous system inflammatory pathways by interferon-alpha: relationship to monoamines and depression. Biol Psychiatry 2009, 65:296-303.
29. Capuron L., Raison C.L., Musselman D.L., Lawson D.H., Nemeroff C.B., Miller A.H. Association of exaggerated HPA axis response to the initial injection of interferon-alpha with development of depression during interferon-alpha therapy. Am J Psychiatry 2003, 160:1342-1345.
30. Capuron L., Neurauter G., Musselman D.L., Lawson D.H., Nemeroff C.B., Fuchs D., et al. Interferon-alpha-induced changes in tryptophan metabolism. relationship to depression and paroxetine treatment. Biol Psychiatry 2003, 54:906-914.
31. Capuron L., Pagnoni G., Demetrashvili M., Woolwine B.J., Nemeroff C.B., Berns G.S., et al. Anterior cingulate activation and error processing during interferon-alpha treatment. Biol Psychiatry 2005, 58:190-196.
32. Bull S.J., Huezo-Diaz P., Binder E.B., Cubells J.F., Ranjith G., Maddock C., et al. Functional polymorphisms in the interleukin-6 and serotonin transporter genes, and depression and fatigue induced by interferon-alpha and ribavirin treatment. Mol Psychiatry 2009, 14:1145.
33. Wichers M.C., Kenis G., Leue C., Koek G., Robaeys G., Maes M. Baseline immune activation as a risk factor for the onset of depression during interferon-alpha treatment. Biol Psychiatry 2006, 60:77-79.
34. Chen D.S., Kuo G.C., Sung J.L., Lai M.Y., Sheu J.C., Chen P.J., et al. Hepatitis C virus infection in an area hyperendemic for hepatitis B and chronic liver disease: the Taiwan experience. J Infect Dis 1990, 162:817-822.
35. Musselman D.L., Lawson D.H., Gumnick J.F., Manatunga A.K., Penna S., Goodkin R.S., et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med 2001, 344:961-966.
36. Wu P.L., Liao K.F., Peng C.Y., Pariante C.M., Su K.P. Manic episode associated with citalopram therapy for interferon-induced depression in a patient with chronic hepatitis C infection. Gen Hosp Psychiatry 2007, 29:374-376.
37. Capuron L., Gumnick J.F., Musselman D.L., Lawson D.H., Reemsnyder A., Nemeroff C.B., et al. Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology 2002, 26:643-652.
38. Connor T.J., Kelliher P., Shen Y., Harkin A., Kelly J.P., Leonard B.E. Effect of subchronic antidepressant treatments on behavioral, neurochemical, and endocrine changes in the forced-swim test. Pharmacol Biochem Behav 2000, 65:591-597.
39. Kubera M., Obuchowicz E., Goehler L., Brzeszcz J., Maes M. In animal models, psychosocial stress-induced (neuro)inflammation, apoptosis and reduced neurogenesis are associated to the onset of depression. Prog Neuropsychopharmacol Biol Psychiatry 2011, 35:744-759.
40. Yirmiya R., Pollak Y., Barak O., Avitsur R., Ovadia H., Bette M., et al. Effects of antidepressant drugs on the behavioral and physiological responses to lipopolysaccharide (LPS) in rodents. Neuropsychopharmacology 2001, 24:531-544.
41. Krass M., Wegener G., Vasar E., Volke V. The antidepressant action of imipramine and venlafaxine involves suppression of nitric oxide synthesis. Behav Brain Res 2011, 218:57-63.
42. Nahman S, Belmaker RH, Azab AN. Effects of lithium on lipopolysaccharide-induced inflammation in rat primary glia cells. Innate Immun; in press [Epub ahead of print].
43. Zhang Z., Zhang Z.Y., Fauser U., Schluesener H.J. Valproic acid attenuates inflammation in experimental autoimmune neuritis. Cell Mol Life Sci 2008, 65:4055-4065.
44. Bian Q., Kato T., Monji A., Hashioka S., Mizoguchi Y., Horikawa H., et al. The effect of atypical antipsychotics, perospirone, ziprasidone and quetiapine on microglial activation induced by interferon-gamma. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:42-48.
45. Kim H., Bang J., Chang H.W., Kim J.Y., Park K.U., Kim S.H., et al. Anti-inflammatory effect of quetiapine on collagen-induced arthritis of mouse. Eur J Pharmacol 2012, 678:55-60.
46. Hestad K.A., Tonseth S., Stoen C.D., Ueland T., Aukrust P. Raised plasma levels of tumor necrosis factor alpha in patients with depression: normalization during electroconvulsive therapy. J ECT 2003, 19:183-188.
47. Petersen A.M., Pedersen B.K. The role of IL-6 in mediating the anti-inflammatory effects of exercise. J Physiol Pharmacol 2006, 57:43-51.
48. Thornton L.M., Andersen B.L., Schuler T.A., Carson W.E. A psychological intervention reduces inflammatory markers by alleviating depressive symptoms: secondary analysis of a randomized controlled trial. Psychosom Med 2009, 71:715-724.
49. Maes M., Fisar Z., Medina M., Scapagnini G., Nowak G., Berk M. New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates-Nrf2 activators and GSK-3 inhibitors. Inflammopharmacology 2012, [Epub ahead of print].
50. Maas D.W., Westendorp R.G., Willems J.M., de Craen A.J., van der Mast R.C. TNF-alpha antagonist infliximab in the treatment of depression in older adults: results of a prematurely ended, randomized, placebo-controlled trial. J Clin Psychopharmacol 2010, 30:343-345.
51. Muller N., Schwarz M.J., Dehning S., Douhe A., Cerovecki A., Goldstein-Muller B., et al. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry 2006, 11:680-684.
52. Bjarnason I., Takeuchi K. Intestinal permeability in the pathogenesis of NSAID-induced enteropathy. J Gastroenterol 2009, 44:23-29.
53. Raison C.L., Lowry C.A., Rook G.A. Inflammation, sanitation, and consternation: loss of contact with coevolved, tolerogenic microorganisms and the pathophysiology and treatment of major depression. Arch Gen Psychiatry 2010, 67:1211-1224.
54. Hibbeln J.R., Nieminen L.R., Blasbalg T.L., Riggs J.A., Lands W.E. Healthy intakes of n-3 and n-6 fatty acids: estimations considering worldwide diversity. Am J Clin Nutr 2006, 83:1483S-1493S.
55. Lin P.Y., Huang S.Y., Su K.P. A meta-analytic review of polyunsaturated fatty acid compositions in patients with depression. Biol Psychiatry 2010, 68:140-147.
56. McNamara R.K., Hahn C.G., Jandacek R., Rider T., Tso P., Stanford K.E., et al. Selective deficits in the omega-3 fatty acid docosahexaenoic acid in the postmortem orbitofrontal cortex of patients with major depressive disorder. Biol Psychiatry 2007, 62:17-24.
57. De Vriese S.R., Christophe A.B., Maes M. Lowered serum n-3 polyunsaturated fatty acid (PUFA) levels predict the occurrence of postpartum depression: further evidence that lowered n-PUFAs are related to major depression. Life Sci 2003, 73:3181-3187.
58. Green P., Hermesh H., Monselise A., Marom S., Presburger G., Weizman A. Red cell membrane omega-3 fatty acids are decreased in nondepressed patients with social anxiety disorder. Eur Neuropsychopharmacol 2006, 16:107-113.
59. Chiu C.C., Huang S.Y., Su K.P., Lu M.L., Huang M.C., Chen C.C., et al. Polyunsaturated fatty acid deficit in patients with bipolar mania. Eur Neuropsychopharmacol 2003, 13:99-103.
60. Freeman M.P., Hibbeln J.R., Wisner K.L., Davis J.M., Mischoulon D., Peet M., et al. Omega-3 fatty acids: evidence basis for treatment and future research in psychiatry. J Clin Psychiatry 2006, 67:1954-1967.
61. Lin P.Y., Su K.P. A meta-analytic review of double-blind, placebo-controlled trials of antidepressant efficacy of omega-3 fatty acids. J Clin Psychiatry 2007, 68:1056-1061.
62. Freeman M.P., Mischoulon D., Tedeschini E., Goodness T., Cohen L.S., Fava M., et al. Complementary and alternative medicine for major depressive disorder: a meta-analysis of patient characteristics, placebo-response rates, and treatment outcomes relative to standard antidepressants. J Clin Psychiatry 2010, 71:682-688.
63. Sublette M.E., Ellis S.P., Geant A.L., Mann J.J. Meta-analysis of the effects of eicosapentaenoic acid (EPA) in clinical trials in depression. J Clin Psychiatry 2011, 72:1577-1584.
64. Appleton K.M., Hayward R.C., Gunnell D., Peters T.J., Rogers P.J., Kessler D., et al. Effects of n-3 long-chain polyunsaturated fatty acids on depressed mood: systematic review of published trials. Am J Clin Nutr 2006, 84:1308-1316.
65. Rogers P.J., Appleton K.M., Kessler D., Peters T.J., Gunnell D., Hayward R.C., et al. No effect of n-3 long-chain polyunsaturated fatty acid (EPA and DHA) supplementation on depressed mood and cognitive function: a randomised controlled trial. Br J Nutr 2008, 99:421-431.
66. Bloch MH, Hannestad J. Omega-3 fatty acids for the treatment of depression: systematic review and meta-analysis. Mol Psychiatry; in press [Epub ahead of print].
67. Appleton K.M., Rogers P.J., Ness A.R. Updated systematic review and meta-analysis of the effects of n-3 long-chain polyunsaturated fatty acids on depressed mood. Am J Clin Nutr 2010, 91:757-770.
68. Ness A.R., Gallacher J.E., Bennett P.D., Gunnell D.J., Rogers P.J., Kessler D., et al. Advice to eat fish and mood: a randomised controlled trial in men with angina. Nutr Neurosci 2003, 6:63-65.
69. Su K.P., Shen W.W., Huang S.Y. Are omega3 fatty acids beneficial in depression but not mania?. Arch Gen Psychiatry 2000, 57:716-717.
70. Sarris J., Mischoulon D., Schweitzer I. Omega-3 for bipolar disorder: meta-analyses of use in mania and bipolar depression. J Clin Psychiatry 2012, 73:81-86.
71. Chiu C.C., Huang S.Y., Chen C.C., Su K.P. Omega-3 fatty acids are more beneficial in the depressive phase than in the manic phase in patients with bipolar I disorder. J Clin Psychiatry 2005, 66:1613-1614.
72. Chiu C.C., Huang S.Y., Shen W.W., Su K.P. Omega-3 fatty acids for depression in pregnancy. Am J Psychiatry 2003, 160:385.
73. Su K.P., Huang S.Y., Chiu T.H., Huang K.C., Huang C.L., Chang H.C., et al. Omega-3 fatty acids for major depressive disorder during pregnancy: results from a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2008, 69:644-651.
74. Freeman M.P. Omega-3 fatty acids and perinatal depression: a review of the literature and recommendations for future research. Prostaglandins Leukot Essent Fatty Acids 2006, 75:291-297.
75. Nemets H., Nemets B., Apter A., Bracha Z., Belmaker R.H. Omega-3 treatment of childhood depression: a controlled, double-blind pilot study. Am J Psychiatry 2006, 163:1098-1100.
76. Hallahan B., Hibbeln J.R., Davis J.M., Garland M.R. Omega-3 fatty acid supplementation in patients with recurrent self-harm. Single-centre double-blind randomised controlled trial. Br J Psychiatry 2007, 190:118-122.
77. Freeman M.P., Hibbeln J.R., Silver M., Hirschberg A.M., Wang B., Yule A.M., et al. Omega-3 fatty acids for major depressive disorder associated with the menopausal transition: a preliminary open trial. Menopause 2011, 18:279-284.
78. Zanarini M.C., Frankenburg F.R. Omega-3 fatty acid treatment of women with borderline personality disorder: a double-blind, placebo-controlled pilot study. Am J Psychiatry 2003, 160:167-169.
79. Carlezon W.A., Mague S.D., Parow A.M., Stoll A.L., Cohen B.M., Renshaw P.F. Antidepressant-like effects of uridine and omega-3 fatty acids are potentiated by combined treatment in rats. Biol Psychiatry 2005, 57:343-350.
80. Huang S.Y., Yang H.T., Chiu C.C., Pariante C.M., Su K.P. Omega-3 fatty acids on the forced-swimming test. J Psychiatr Res 2008, 42:58-63.
81. Rapoport S.I., Bosetti F. Do lithium and anticonvulsants target the brain arachidonic acid cascade in bipolar disorder?. Arch Gen Psychiatry 2002, 59:592-596.
82. Maes M., Christophe A., Delanghe J., Altamura C., Neels H., Meltzer H.Y. Lowered omega3 polyunsaturated fatty acids in serum phospholipids and cholesteryl esters of depressed patients. Psychiatry Res 1999, 85:275-291.
83. Noponen M., Sanfilipo M., Samanich K., Ryer H., Ko G., Angrist B., et al. Elevated PLA2 activity in schizophrenics and other psychiatric patients. Biol Psychiatry 1993, 34:641-649.
84. Chang M.C., Contreras M.A., Rosenberger T.A., Rintala J.J., Bell J.M., Rapoport S.I. Chronic valproate treatment decreases the in vivo turnover of arachidonic acid in brain phospholipids: a possible common effect of mood stabilizers. J Neurochem 2001, 77:796-803.
85. Chalon S., Vancassel S., Zimmer L., Guilloteau D., Durand G. Polyunsaturated fatty acids and cerebral function: focus on monoaminergic neurotransmission. Lipids 2001, 36:937-944.
86. Murck H., Song C., Horrobin D.F., Uhr M. Ethyl-eicosapentaenoate and dexamethasone resistance in therapy-refractory depression. Int J Neuropsychopharmacol 2004, 7:341-349.
87. Bays H.E. Safety considerations with omega-3 fatty acid therapy. Am J Cardiol 2007, 99:35C-43C.
88. Bays H. Clinical overview of Omacor: a concentrated formulation of omega-3 polyunsaturated fatty acids. Am J Cardiol 2006, 98:71i-76i.
89. Harris W.S. Expert opinion: omega-3 fatty acids and bleeding-cause for concern?. Am J Cardiol 2007, 99:44C-46C.
90. Chiu C.C., Liu J.P., Su K.P. The use of omega-3 fatty acids in treatment of depression: the lights and shadows. Psychiatr Times 2008, 25:76-80.
91. Kinrys G. Hypomania associated with omega3 fatty acids. Arch Gen Psychiatry 2000, 57:715-716.